APO Research
Talk to an analyst

APO RESEARCH · REPORT

Single-target Anti-VEGF Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Single-target Anti-VEGF Drugs Industry Growth and Trends Forecast to 2032

27 December 202593 pages

Choose your research edition.

Industry ResearchSingle-target Anti-VEGF Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Single-target Anti-VEGF Drugs Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Single-target Anti-VEGF Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Single-target Anti-VEGF Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Single-target Anti-VEGF Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Single-target Anti-VEGF Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Single-target Anti-VEGF Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Single-target Anti-VEGF Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Single-target Anti-VEGF Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Single-target Anti-VEGF Drugs include Roche, Chengdu Kanghong Pharmaceutical, Samsung Bioepis, Regeneron Pharmaceuticals, Novartis, Coherus BioSciences and Biocon Biologics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Single-target Anti-VEGF Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Single-target Anti-VEGF Drugs market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Single-target Anti-VEGF Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Single-target Anti-VEGF Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Single-target Anti-VEGF Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Single-target Anti-VEGF Drugs Market by Company

Roche

Chengdu Kanghong Pharmaceutical

Samsung Bioepis

Regeneron Pharmaceuticals

Novartis

Coherus BioSciences

Biocon Biologics

Single-target Anti-VEGF Drugs Segment by Type

Ranibizumab

Conbercept

Faricimab

Brolucizumab

Aflibercept

Other

Single-target Anti-VEGF Drugs Segment by Application

Diabetic Retinopathy

Age-related Macular Degeneration

Other

Single-target Anti-VEGF Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Single-target Anti-VEGF Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Single-target Anti-VEGF Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Single-target Anti-VEGF Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Single-target Anti-VEGF Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Single-target Anti-VEGF Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Ranibizumab Table 2. Major Company of Conbercept Table 3. Major Company of Faricimab Table 4. Major Company of Brolucizumab Table 5. Major Company of Aflibercept Table 6. Major Company of Other Table 7. Global Single-target Anti-VEGF Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 8. Global Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (K Units) Table 9. Global Single-target Anti-VEGF Drugs Sales Market Share in Volume by Type (2021-2026) Table 10. Global Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (US$ Million) Table 11. Global Single-target Anti-VEGF Drugs Sales Market Share in Value by Type (2021-2026) Table 12. Global Single-target Anti-VEGF Drugs Price by Type (2021-2026) & (US$/Unit) Table 13. Global Single-target Anti-VEGF Drugs Sales by Type (2027-2032) & (K Units) Table 14. Global Single-target Anti-VEGF Drugs Sales Market Share in Volume by Type (2027-2032) Table 15. Global Single-target Anti-VEGF Drugs Sales by Type (2027-2032) & (US$ Million) Table 16. Global Single-target Anti-VEGF Drugs Sales Market Share in Value by Type (2027-2032) Table 17. Global Single-target Anti-VEGF Drugs Price by Type (2027-2032) & (US$/Unit) Table 18. North America Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (K Units) Table 19. North America Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (US$ Million) Table 20. Europe Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (K Units) Table 21. Europe Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (US$ Million) Table 22. Asia-Pacific Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (K Units) Table 23. Asia-Pacific Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (US$ Million) Table 24. Latin America Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (K Units) Table 25. Latin America Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (US$ Million) Table 26. Middle East and Africa Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (K Units) Table 27. Middle East and Africa Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (US$ Million) Table 28. Single-target Anti-VEGF Drugs Industry Trends Table 29. Single-target Anti-VEGF Drugs Industry Drivers Table 30. Single-target Anti-VEGF Drugs Industry Opportunities and Challenges Table 31. Single-target Anti-VEGF Drugs Industry Restraints Table 32. Global Single-target Anti-VEGF Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 33. Global Single-target Anti-VEGF Drugs Revenue Market Share by Company (2021-2026) Table 34. Global Single-target Anti-VEGF Drugs Sales by Company (2021-2026) & (K Units) Table 35. Global Single-target Anti-VEGF Drugs Sales Share by Company (2021-2026) Table 36. Global Single-target Anti-VEGF Drugs Market Price by Company (2021-2026) & (US$/Unit) Table 37. Global Single-target Anti-VEGF Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 38. Global Single-target Anti-VEGF Drugs Major Company Production Sites and Headquarters Table 39. Global Single-target Anti-VEGF Drugs Company, Product Type & Application Table 40. Global Single-target Anti-VEGF Drugs Company Establishment Date Table 41. Global Company Market Concentration Ratio (CR5 and HHI) Table 42. Global Single-target Anti-VEGF Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global Single-target Anti-VEGF Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global Single-target Anti-VEGF Drugs Sales by Region (2021-2026) & (K Units) Table 45. Global Single-target Anti-VEGF Drugs Sales Market Share in Volume by Region (2021-2026) Table 46. Global Single-target Anti-VEGF Drugs Sales by Region (2021-2026) & (US$ Million) Table 47. Global Single-target Anti-VEGF Drugs Sales Market Share in Value by Region (2021-2026) Table 48. Global Single-target Anti-VEGF Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 49. Global Single-target Anti-VEGF Drugs Sales by Region (2027-2032) & (K Units) Table 50. Global Single-target Anti-VEGF Drugs Sales Market Share in Volume by Region (2027-2032) Table 51. Global Single-target Anti-VEGF Drugs Sales by Region (2027-2032) & (US$ Million) Table 52. Global Single-target Anti-VEGF Drugs Sales Market Share in Value by Region (2027-2032) Table 53. Global Single-target Anti-VEGF Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 54. Global Single-target Anti-VEGF Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 55. Global Single-target Anti-VEGF Drugs Sales by Application (2021-2026) & (K Units) Table 56. Global Single-target Anti-VEGF Drugs Sales Market Share in Volume by Application (2021-2026) Table 57. Global Single-target Anti-VEGF Drugs Sales by Application (2021-2026) & (US$ Million) Table 58. Global Single-target Anti-VEGF Drugs Sales Market Share in Value by Application (2021-2026) Table 59. Global Single-target Anti-VEGF Drugs Price by Application (2021-2026) & (US$/Unit) Table 60. Global Single-target Anti-VEGF Drugs Sales by Application (2027-2032) & (K Units) Table 61. Global Single-target Anti-VEGF Drugs Sales Market Share in Volume by Application (2027-2032) Table 62. Global Single-target Anti-VEGF Drugs Sales by Application (2027-2032) & (US$ Million) Table 63. Global Single-target Anti-VEGF Drugs Sales Market Share in Value by Application (2027-2032) Table 64. Global Single-target Anti-VEGF Drugs Price by Application (2027-2032) & (US$/Unit) Table 65. North America Single-target Anti-VEGF Drugs Sales by Application (2021-2026) & (K Units) Table 66. North America Single-target Anti-VEGF Drugs Sales by Application (2021-2026) & (US$ Million) Table 67. Europe Single-target Anti-VEGF Drugs Sales by Application (2021-2026) & (K Units) Table 68. Europe Single-target Anti-VEGF Drugs Sales by Application (2021-2026) & (US$ Million) Table 69. Asia-Pacific Single-target Anti-VEGF Drugs Sales by Application (2021-2026) & (K Units) Table 70. Asia-Pacific Single-target Anti-VEGF Drugs Sales by Application (2021-2026) & (US$ Million) Table 71. Latin America Single-target Anti-VEGF Drugs Sales by Application (2021-2026) & (K Units) Table 72. Latin America Single-target Anti-VEGF Drugs Sales by Application (2021-2026) & (US$ Million) Table 73. Middle East and Africa Single-target Anti-VEGF Drugs Sales by Application (2021-2026) & (K Units) Table 74. Middle East and Africa Single-target Anti-VEGF Drugs Sales by Application (2021-2026) & (US$ Million) Table 75. Roche Company Information Table 76. Roche Business Overview Table 77. Roche Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Roche Single-target Anti-VEGF Drugs Product Portfolio Table 79. Roche Recent Development Table 80. Chengdu Kanghong Pharmaceutical Company Information Table 81. Chengdu Kanghong Pharmaceutical Business Overview Table 82. Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Product Portfolio Table 84. Chengdu Kanghong Pharmaceutical Recent Development Table 85. Samsung Bioepis Company Information Table 86. Samsung Bioepis Business Overview Table 87. Samsung Bioepis Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Samsung Bioepis Single-target Anti-VEGF Drugs Product Portfolio Table 89. Samsung Bioepis Recent Development Table 90. Regeneron Pharmaceuticals Company Information Table 91. Regeneron Pharmaceuticals Business Overview Table 92. Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Product Portfolio Table 94. Regeneron Pharmaceuticals Recent Development Table 95. Novartis Company Information Table 96. Novartis Business Overview Table 97. Novartis Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Novartis Single-target Anti-VEGF Drugs Product Portfolio Table 99. Novartis Recent Development Table 100. Coherus BioSciences Company Information Table 101. Coherus BioSciences Business Overview Table 102. Coherus BioSciences Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Coherus BioSciences Single-target Anti-VEGF Drugs Product Portfolio Table 104. Coherus BioSciences Recent Development Table 105. Biocon Biologics Company Information Table 106. Biocon Biologics Business Overview Table 107. Biocon Biologics Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Biocon Biologics Single-target Anti-VEGF Drugs Product Portfolio Table 109. Biocon Biologics Recent Development Table 110. North America Single-target Anti-VEGF Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 111. North America Single-target Anti-VEGF Drugs Sales by Country (2021-2026) & (K Units) Table 112. North America Single-target Anti-VEGF Drugs Sales Market Share by Country (2021-2026) Table 113. North America Single-target Anti-VEGF Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 114. North America Single-target Anti-VEGF Drugs Sales Market Share Forecast by Country (2027-2032) Table 115. North America Single-target Anti-VEGF Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 116. North America Single-target Anti-VEGF Drugs Market Size by Country (2021-2026) & (US$ Million) Table 117. North America Single-target Anti-VEGF Drugs Market Share by Country (2021-2026) Table 118. North America Single-target Anti-VEGF Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 119. North America Single-target Anti-VEGF Drugs Market Share Forecast by Country (2027-2032) Table 120. Europe Single-target Anti-VEGF Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 121. Europe Single-target Anti-VEGF Drugs Sales by Country (2021-2026) & (K Units) Table 122. Europe Single-target Anti-VEGF Drugs Sales Market Share by Country (2021-2026) Table 123. Europe Single-target Anti-VEGF Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 124. Europe Single-target Anti-VEGF Drugs Sales Market Share Forecast by Country (2027-2032) Table 125. Europe Single-target Anti-VEGF Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 126. Europe Single-target Anti-VEGF Drugs Market Size by Country (2021-2026) & (US$ Million) Table 127. Europe Single-target Anti-VEGF Drugs Market Share by Country (2021-2026) Table 128. Europe Single-target Anti-VEGF Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 129. Europe Single-target Anti-VEGF Drugs Market Share Forecast by Country (2027-2032) Table 130. Asia-Pacific Single-target Anti-VEGF Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 131. Asia-Pacific Single-target Anti-VEGF Drugs Sales by Country (2021-2026) & (K Units) Table 132. Asia-Pacific Single-target Anti-VEGF Drugs Sales Market Share by Country (2021-2026) Table 133. Asia-Pacific Single-target Anti-VEGF Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 134. Asia-Pacific Single-target Anti-VEGF Drugs Sales Market Share Forecast by Country (2027-2032) Table 135. Asia-Pacific Single-target Anti-VEGF Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 136. Asia-Pacific Single-target Anti-VEGF Drugs Market Size by Country (2021-2026) & (US$ Million) Table 137. Asia-Pacific Single-target Anti-VEGF Drugs Market Share by Country (2021-2026) Table 138. Asia-Pacific Single-target Anti-VEGF Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 139. Asia-Pacific Single-target Anti-VEGF Drugs Market Share Forecast by Country (2027-2032) Table 140. Latin America Single-target Anti-VEGF Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 141. Latin America Single-target Anti-VEGF Drugs Sales by Country (2021-2026) & (K Units) Table 142. Latin America Single-target Anti-VEGF Drugs Sales Market Share by Country (2021-2026) Table 143. Latin America Single-target Anti-VEGF Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 144. Latin America Single-target Anti-VEGF Drugs Sales Market Share Forecast by Country (2027-2032) Table 145. Latin America Single-target Anti-VEGF Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 146. Latin America Single-target Anti-VEGF Drugs Market Size by Country (2021-2026) & (US$ Million) Table 147. Latin America Single-target Anti-VEGF Drugs Market Share by Country (2021-2026) Table 148. Latin America Single-target Anti-VEGF Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 149. Latin America Single-target Anti-VEGF Drugs Market Share Forecast by Country (2027-2032) Table 150. Middle East and Africa Single-target Anti-VEGF Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 151. Middle East and Africa Single-target Anti-VEGF Drugs Sales by Country (2021-2026) & (K Units) Table 152. Middle East and Africa Single-target Anti-VEGF Drugs Sales Market Share by Country (2021-2026) Table 153. Middle East and Africa Single-target Anti-VEGF Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 154. Middle East and Africa Single-target Anti-VEGF Drugs Sales Market Share Forecast by Country (2027-2032) Table 155. Middle East and Africa Single-target Anti-VEGF Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 156. Middle East and Africa Single-target Anti-VEGF Drugs Market Size by Country (2021-2026) & (US$ Million) Table 157. Middle East and Africa Single-target Anti-VEGF Drugs Market Share by Country (2021-2026) Table 158. Middle East and Africa Single-target Anti-VEGF Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 159. Middle East and Africa Single-target Anti-VEGF Drugs Market Share Forecast by Country (2027-2032) Table 160. Key Raw Materials Table 161. Raw Materials Key Suppliers Table 162. Single-target Anti-VEGF Drugs Distributors List Table 163. Single-target Anti-VEGF Drugs Customers List Table 164. Research Programs/Design for This Report Table 165. Authors List of This Report Table 166. Secondary Sources Table 167. Primary Sources List of Figures Figure 1. Single-target Anti-VEGF Drugs Image Figure 2. Global Single-target Anti-VEGF Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Single-target Anti-VEGF Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Single-target Anti-VEGF Drugs Sales (2021-2032) & (K Units) Figure 5. Ranibizumab Image Figure 6. Global Ranibizumab Sales YoY Growth (2021-2032) & (K Units) Figure 7. Conbercept Image Figure 8. Global Conbercept Sales YoY Growth (2021-2032) & (K Units) Figure 9. Faricimab Image Figure 10. Global Faricimab Sales YoY Growth (2021-2032) & (K Units) Figure 11. Brolucizumab Image Figure 12. Global Brolucizumab Sales YoY Growth (2021-2032) & (K Units) Figure 13. Aflibercept Image Figure 14. Global Aflibercept Sales YoY Growth (2021-2032) & (K Units) Figure 15. Other Image Figure 16. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 17. Global Single-target Anti-VEGF Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 18. Global Single-target Anti-VEGF Drugs Market Share by Type 2025 VS 2032 Figure 19. North America Single-target Anti-VEGF Drugs Sales Market Share in Volume by Type in 2025 Figure 20. North America Single-target Anti-VEGF Drugs Sales Market Share in Value by Type in 2025 Figure 21. Europe Single-target Anti-VEGF Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Europe Single-target Anti-VEGF Drugs Sales Market Share in Value by Type in 2025 Figure 23. Asia-Pacific Single-target Anti-VEGF Drugs Sales Market Share in Volume by Type in 2025 Figure 24. Asia-Pacific Single-target Anti-VEGF Drugs Sales Market Share in Value by Type in 2025 Figure 25. Latin America Single-target Anti-VEGF Drugs Sales Market Share in Volume by Type in 2025 Figure 26. Latin America Single-target Anti-VEGF Drugs Sales Market Share in Value by Type in 2025 Figure 27. Middle East and Africa Single-target Anti-VEGF Drugs Sales Market Share in Volume by Type in 2025 Figure 28. Middle East and Africa Single-target Anti-VEGF Drugs Sales Market Share in Value by Type in 2025 Figure 29. Global Top 5 and 10 Single-target Anti-VEGF Drugs Players Market Share by Revenue in 2025 Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Diabetic Retinopathy Image Figure 32. Global Diabetic Retinopathy Sales YoY Growth (2021-2032) & (K Units) Figure 33. Age-related Macular Degeneration Image Figure 34. Global Age-related Macular Degeneration Sales YoY Growth (2021-2032) & (K Units) Figure 35. Other Image Figure 36. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 37. Global Single-target Anti-VEGF Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Single-target Anti-VEGF Drugs Market Share by Application 2025 VS 2032 Figure 39. North America Single-target Anti-VEGF Drugs Sales Market Share in Volume by Application in 2025 Figure 40. North America Single-target Anti-VEGF Drugs Sales Market Share in Value by Application in 2025 Figure 41. Europe Single-target Anti-VEGF Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Europe Single-target Anti-VEGF Drugs Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific Single-target Anti-VEGF Drugs Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific Single-target Anti-VEGF Drugs Sales Market Share in Value by Application in 2025 Figure 45. Latin America Single-target Anti-VEGF Drugs Sales Market Share in Volume by Application in 2025 Figure 46. Latin America Single-target Anti-VEGF Drugs Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa Single-target Anti-VEGF Drugs Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa Single-target Anti-VEGF Drugs Sales Market Share in Value by Application in 2025 Figure 49. North America Single-target Anti-VEGF Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. North America Single-target Anti-VEGF Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America Single-target Anti-VEGF Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America Single-target Anti-VEGF Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Single-target Anti-VEGF Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Europe Single-target Anti-VEGF Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Single-target Anti-VEGF Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe Single-target Anti-VEGF Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Single-target Anti-VEGF Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Asia-Pacific Single-target Anti-VEGF Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Single-target Anti-VEGF Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific Single-target Anti-VEGF Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Single-target Anti-VEGF Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Latin America Single-target Anti-VEGF Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Single-target Anti-VEGF Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America Single-target Anti-VEGF Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Single-target Anti-VEGF Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 66. Middle East and Africa Single-target Anti-VEGF Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Single-target Anti-VEGF Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa Single-target Anti-VEGF Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Single-target Anti-VEGF Drugs Value Chain Figure 70. Key Raw Materials Price Figure 71. Manufacturing Cost Structure Figure 72. Single-target Anti-VEGF Drugs Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Ranibizumab
  • Conbercept
  • Faricimab
  • Brolucizumab
  • Aflibercept
  • Other
Applications
  • Diabetic Retinopathy
  • Age-related Macular Degeneration
  • Other
Companies covered
  • Roche
  • Chengdu Kanghong Pharmaceutical
  • Samsung Bioepis
  • Regeneron Pharmaceuticals
  • Novartis
  • Coherus BioSciences
  • Biocon Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Single-target Anti-VEGF Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Single-target Anti-VEGF Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Single-target Anti-VEGF Drugs Market by Type
  6. 1.3.1 Ranibizumab
  7. 1.3.2 Conbercept
  8. 1.3.3 Faricimab
  9. 1.3.4 Brolucizumab
  10. 1.3.5 Aflibercept
  11. 1.3.6 Other
  12. 1.4 Global Single-target Anti-VEGF Drugs Market Size by Type
  13. 1.4.1 Global Single-target Anti-VEGF Drugs Market Size Overview by Type (2021-2032)
  14. 1.4.2 Global Single-target Anti-VEGF Drugs Historic Market Size Review by Type (2021-2026)
  15. 1.4.3 Global Single-target Anti-VEGF Drugs Forecasted Market Size by Type (2027-2032)
  16. 1.5 Key Regions Market Size by Type
  17. 1.5.1 North America Single-target Anti-VEGF Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.2 Europe Single-target Anti-VEGF Drugs Sales Breakdown by Type (2021-2026)
  19. 1.5.3 Asia-Pacific Single-target Anti-VEGF Drugs Sales Breakdown by Type (2021-2026)
  20. 1.5.4 South America Single-target Anti-VEGF Drugs Sales Breakdown by Type (2021-2026)
  21. 1.5.5 Middle East and Africa Single-target Anti-VEGF Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Single-target Anti-VEGF Drugs Industry Trends
  2. 2.2 Single-target Anti-VEGF Drugs Industry Drivers
  3. 2.3 Single-target Anti-VEGF Drugs Industry Opportunities and Challenges
  4. 2.4 Single-target Anti-VEGF Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Single-target Anti-VEGF Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Single-target Anti-VEGF Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Single-target Anti-VEGF Drugs Price (2021-2026)
  4. 3.4 Global Single-target Anti-VEGF Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Single-target Anti-VEGF Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Single-target Anti-VEGF Drugs Company, Product Type & Application
  7. 3.7 Global Single-target Anti-VEGF Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Single-target Anti-VEGF Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Single-target Anti-VEGF Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Single-target Anti-VEGF Drugs Tier 1, Tier 2, and Tier 3
4 Single-target Anti-VEGF Drugs Regional Status and Outlook
  1. 4.1 Global Single-target Anti-VEGF Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Single-target Anti-VEGF Drugs Historic Market Size by Region
  3. 4.2.1 Global Single-target Anti-VEGF Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Single-target Anti-VEGF Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Single-target Anti-VEGF Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Single-target Anti-VEGF Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Single-target Anti-VEGF Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Single-target Anti-VEGF Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Single-target Anti-VEGF Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Single-target Anti-VEGF Drugs by Application
  1. 5.1 Single-target Anti-VEGF Drugs Market by Application
  2. 5.1.1 Diabetic Retinopathy
  3. 5.1.2 Age-related Macular Degeneration
  4. 5.1.3 Other
  5. 5.2 Global Single-target Anti-VEGF Drugs Market Size by Application
  6. 5.2.1 Global Single-target Anti-VEGF Drugs Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Single-target Anti-VEGF Drugs Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Single-target Anti-VEGF Drugs Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Single-target Anti-VEGF Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Single-target Anti-VEGF Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Single-target Anti-VEGF Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Single-target Anti-VEGF Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Single-target Anti-VEGF Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Roche
  2. 6.1.1 Roche Company Information
  3. 6.1.2 Roche Business Overview
  4. 6.1.3 Roche Single-target Anti-VEGF Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Roche Single-target Anti-VEGF Drugs Product Portfolio
  6. 6.1.5 Roche Recent Developments
  7. 6.2 Chengdu Kanghong Pharmaceutical
  8. 6.2.1 Chengdu Kanghong Pharmaceutical Company Information
  9. 6.2.2 Chengdu Kanghong Pharmaceutical Business Overview
  10. 6.2.3 Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Product Portfolio
  12. 6.2.5 Chengdu Kanghong Pharmaceutical Recent Developments
  13. 6.3 Samsung Bioepis
  14. 6.3.1 Samsung Bioepis Company Information
  15. 6.3.2 Samsung Bioepis Business Overview
  16. 6.3.3 Samsung Bioepis Single-target Anti-VEGF Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Samsung Bioepis Single-target Anti-VEGF Drugs Product Portfolio
  18. 6.3.5 Samsung Bioepis Recent Developments
  19. 6.4 Regeneron Pharmaceuticals
  20. 6.4.1 Regeneron Pharmaceuticals Company Information
  21. 6.4.2 Regeneron Pharmaceuticals Business Overview
  22. 6.4.3 Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Product Portfolio
  24. 6.4.5 Regeneron Pharmaceuticals Recent Developments
  25. 6.5 Novartis
  26. 6.5.1 Novartis Company Information
  27. 6.5.2 Novartis Business Overview
  28. 6.5.3 Novartis Single-target Anti-VEGF Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Novartis Single-target Anti-VEGF Drugs Product Portfolio
  30. 6.5.5 Novartis Recent Developments
  31. 6.6 Coherus BioSciences
  32. 6.6.1 Coherus BioSciences Company Information
  33. 6.6.2 Coherus BioSciences Business Overview
  34. 6.6.3 Coherus BioSciences Single-target Anti-VEGF Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Coherus BioSciences Single-target Anti-VEGF Drugs Product Portfolio
  36. 6.6.5 Coherus BioSciences Recent Developments
  37. 6.7 Biocon Biologics
  38. 6.7.1 Biocon Biologics Company Information
  39. 6.7.2 Biocon Biologics Business Overview
  40. 6.7.3 Biocon Biologics Single-target Anti-VEGF Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Biocon Biologics Single-target Anti-VEGF Drugs Product Portfolio
  42. 6.7.5 Biocon Biologics Recent Developments
7 North America by Country
  1. 7.1 North America Single-target Anti-VEGF Drugs Sales by Country
  2. 7.1.1 North America Single-target Anti-VEGF Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Single-target Anti-VEGF Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Single-target Anti-VEGF Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Single-target Anti-VEGF Drugs Market Size by Country
  6. 7.2.1 North America Single-target Anti-VEGF Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Single-target Anti-VEGF Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Single-target Anti-VEGF Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Single-target Anti-VEGF Drugs Sales by Country
  2. 8.1.1 Europe Single-target Anti-VEGF Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Single-target Anti-VEGF Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Single-target Anti-VEGF Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Single-target Anti-VEGF Drugs Market Size by Country
  6. 8.2.1 Europe Single-target Anti-VEGF Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Single-target Anti-VEGF Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Single-target Anti-VEGF Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Single-target Anti-VEGF Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Single-target Anti-VEGF Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Single-target Anti-VEGF Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Single-target Anti-VEGF Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Single-target Anti-VEGF Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Single-target Anti-VEGF Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Single-target Anti-VEGF Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Single-target Anti-VEGF Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Single-target Anti-VEGF Drugs Sales by Country
  2. 10.1.1 South America Single-target Anti-VEGF Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Single-target Anti-VEGF Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Single-target Anti-VEGF Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Single-target Anti-VEGF Drugs Market Size by Country
  6. 10.2.1 South America Single-target Anti-VEGF Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Single-target Anti-VEGF Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Single-target Anti-VEGF Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Single-target Anti-VEGF Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Single-target Anti-VEGF Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Single-target Anti-VEGF Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Single-target Anti-VEGF Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Single-target Anti-VEGF Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Single-target Anti-VEGF Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Single-target Anti-VEGF Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Single-target Anti-VEGF Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Single-target Anti-VEGF Drugs Value Chain Analysis
  2. 12.1.1 Single-target Anti-VEGF Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Single-target Anti-VEGF Drugs Production Mode & Process
  7. 12.2 Single-target Anti-VEGF Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Single-target Anti-VEGF Drugs Distributors
  10. 12.2.3 Single-target Anti-VEGF Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst